Navigation Links
Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay
Date:10/2/2008

rrhage among NSCLC patients with predominantly squamous histology. This has led patients with squamous-cell histology to be regarded by many as inappropriate candidates for therapy with this drug. In addition, several other targeted drugs for NSCLC currently under development may require this type of accurate differentiation due to different side effect profiles or different levels of efficacy.

Combining Rosetta Genomics' proprietary microRNA extraction technology from FFPE samples, sensitive quantification platforms, and microRNA molecular biomarkers identified by the company, Rosetta Genomics has developed a test which differentiates squamous cell carcinoma of the lung from non-squamous NSCLC. This test, which is the subject of the study to be conducted at John Hopkins, is in the final stages of development and is expected to be commercially available by the fourth quarter of 2008.

In July, Columbia University Medical Center's (CUMC) High Complexity Molecular Pathology Laboratory received the approval of the New York State regulators for a test differentiating Squamous NSCLC from other NSCLC. This test, which is based on Rosetta Genomics' technology, exhibited sensitivity of 96 percent and specificity of 90 percent.

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Johns Hopkins University

Founded in 1876, the Johns Hopkins University was the first research unive
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
2. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
3. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
4. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
5. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
6. Queens University Chooses Xceeds Ziplex(R) System for Translational Research
7. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
8. The University of Nottingham in the British Midlands Announces Breakthrough in Parkinsons Disease Research
9. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
10. First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan
11. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
Post Your Comments:
*Name:
*Comment:
*Email: